DelveInsight's comprehensive analysis reveals over 200 companies actively developing 220+ pipeline therapies for gastric cancer treatment, indicating significant industry investment in addressing this disease.
Qurient's Adrixetinib, a selective triple kinase inhibitor, has received FDA approval for a Phase 1b IND application to treat chronic graft-versus-host disease (cGVHD).